Iovance Biotherapeutics Inc
$ 2.85
-0.70%
26 Dec - close price
- Market Cap 1,131,359,000 USD
- Current Price $ 2.85
- High / Low $ 2.99 / 2.82
- Stock P/E N/A
- Book Value 1.82
- EPS -1.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.54 %
- 52 Week High 8.15
- 52 Week Low 1.64
About
Iovance Biotherapeutics, Inc. is a leading clinical-stage biotechnology company headquartered in San Carlos, California, focused on advancing immunotherapy for cancer treatment through its proprietary tumor-infiltrating lymphocyte (TIL) platform. The company’s innovative approach harnesses the body’s immune system to effectively target malignancies, primarily concentrating on melanoma and cervical cancer. With a robust pipeline of therapeutic candidates and a dedication to addressing critical unmet needs in oncology, Iovance is strategically positioned to capitalize on the growing demand for effective cancer treatments, presenting a compelling opportunity for institutional investors in the biopharmaceutical sector.
Analyst Target Price
$8.35
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.5 | -0.64 |
| Estimated EPS | -0.2617 | -0.28 | -0.42 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.45 | -0.8 | -0.74 | -0.64 |
| Surprise | 0.0117 | -0.05 | 0.06 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | -0.01 | 0.33 | 0.24 | 0 |
| Surprise Percentage | 4.4708% | -17.8571% | 14.2857% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | -2.2222% | 41.25% | 32.4324% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2025-12-26 04:10:33
Levi & Korsinsky has launched an investigation into Iovance Biotherapeutics, Inc. (IOVA) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after Iovance reported lower-than-expected Q1 2025 results and slashed its full-year revenue guidance. The company attributed the poor performance to manufacturing facility maintenance and lower Proleukin sales.
2025-12-23 12:10:08
Iovance Biotherapeutics (NASDAQ: IOVA) saw a significant stock jump on December 22, 2025, driven by a Barclays price target increase and high short interest. The article details positive analyst sentiment, routine corporate updates, and the fundamental story centered around Amtagvi's commercial scaling, margin improvement, and promising pipeline developments for 2026. However, it also highlights risks associated with commercial execution, financing, and dilution, crucial for a clinical-stage biotech.
2025-12-23 05:09:49
Iovance Biotherapeutics (NASDAQ:IOVA) saw its shares rise by 8.7% on Monday, closing at $2.6950 with a significant drop in trading volume. Despite this surge, analysts are divided on the company's prospects, with a consensus "Hold" rating and an average price target of $11.10. The clinical-stage biotech, which focuses on tumor-infiltrating lymphocyte (TIL) therapies, continues to report negative earnings and margins while institutional investors have been actively adjusting their positions.
2025-12-23 00:09:49
Iovance Biotherapeutics (NASDAQ: IOVA) stocks recently surged by 9.48% due to FDA designations and promising results, leading Barclays to increase its price target for the company to $10 with an Overweight rating. Despite current operating losses, strategic investments, a strong current ratio, and stock options for new employees suggest a potential for future growth and a positive shift in financial performance. The article emphasizes disciplined, data-driven trading decisions over emotional ones when considering investment in volatile markets.
2025-12-20 10:09:25
Squarepoint Ops LLC significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 115.2% in Q2, bringing its total to 856,569 shares valued at $1.47 million. While analysts have a "Hold" consensus rating with an average target price of $11.10, the company recently reported an EPS beat but missed revenue expectations, remaining unprofitable. Iovance Biotherapeutics is a clinical-stage biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) immunotherapies.
2025-12-19 22:08:26
Iovance Biotherapeutics (IOVA) has granted inducement stock options for 43,150 shares to four new non-executive employees at an exercise price of $2.46 per share. These options vest over three years, with one-third vesting after the first year and the remaining in quarterly installments over the subsequent two years, subject to continued employment. This move aims to retain talent and support the company's long-term goals in developing TIL therapies for cancer.
